Compare NetFlix Inc (NFLX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Repligen Corporation Common Stock — how do they compare? NetFlix Inc trades at $71.08 (market cap $293.85B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: NetFlix Inc is far larger — about 26× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 126 Days and Repligen Corporation Common Stock for 0 Days on average.
| NFLX | RGEN | |
|---|---|---|
Market Cap | $293.85B | $11.31B |
Volume | 39,920,482 | 1,216,919 |
Sector | Media | Health |
52-Week High | $124.13 | $194.57 |
52-Week Low | $67.06 | $102.87 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $299.03B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $70.48, down 0.18% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals with Q2 2026 EPS of $0.80 beating expectations, revenue of $45.18B in 2025, and a net income margin of 28.22%. Recent news highlights strategic moves into live sports and content expansion, while analyst consensus remains bullish with a $89.39 price target.
The outlook for NFLX is positive due to robust earnings growth and expanding profitability, but risks include competitive pressures and market volatility. The stock offers potential upside based on analyst targets, supported by strong cash flow and institutional interest, though investors should monitor execution on live content initiatives.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
